FDA greenlights AbbVie’s next-generation Parkinson’s drug tavapadon (Juvmo) with expected lower side effects

The U.S. Food and Drug Administration has approved AbbVie’s new therapy for Parkinson's disease, tavapadon, which will be marketed under the name Juvmo.

Tavapadon is a dopamine agonist intended to provide the same symptom relief as earlier drugs in the class while aiming to reduce the incidence of side effects that patients often experience.

The approval adds a next‑generation option to AbbVie’s neurology pipeline and could broaden treatment choices for clinicians managing Parkinson's disease.

Analysts see the move as a positive development for AbbVie, potentially strengthening its position in the neuro‑degenerative market.